Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review

Article type: Systematic Review

Keywords: methylphenidate, MPH, ADHD, dual diagnosis, SUD, drug misuse, pharming

Authors: Stefania Chiappini, Pietro Domenico Gramuglia, Alessio Mosca, Clara Cavallotto, Andrea Miuli, John Martin Corkery, Amira Guirguis, Fabrizio Schifano, Giovanni Martinotti

Affiliations: Saint Camillus International University of Health Sciences, School of Medicine, Rome, Italy; Department of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University, Chieti, Italy; Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Swansea University Medical School, Swansea University, Swansea, United Kingdom

License: Copyright © 2024 Chiappini, Gramuglia, Mosca, Cavallotto, Miuli, Corkery, Guirguis, Schifano and Martinotti CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Article links: DOI: 10.3389/fpsyt.2024.1508732  |  PubMed: 39624511  |  PMC: PMC11609911

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (110 KB)

Introduction

Methylphenidate: overview and indications

Methylphenidate is a central nervous system (CNS) stimulant primarily used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It functions by inhibiting the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the brain, which enhances attention, focus, and impulse control (ref. 1, ref. 2). According to the European Medicines Agency (EMA), methylphenidate is indicated for the treatment of ADHD in children and adolescents aged 6 years and older. It is generally recommended as part of a comprehensive treatment program that includes psychological, educational, and social measures. In some cases, it may also be prescribed for adults with ADHD, although this is less common (ref. 1). Methylphenidate may also be prescribed off-label for narcolepsy (ref. 1). In the United States (US) the Food and Drug Administration (FDA) has approved methylphenidate for the treatment of ADHD in children aged 6 and older, adolescents, and adults. It is typically used as part of a broader treatment strategy, including behavioural therapy and other interventions (ref. 2). In the US, it is also approved for the treatment of narcolepsy in adults, helping to manage symptoms of excessive daytime sleepiness (ref. 2).

Methylphenidate formulations: overview and key differences

Methylphenidate is available in various formulations, each designed to optimize the pharmacokinetic profile, enhance patient adherence, and tailor the therapeutic effect to individual needs. The differences in these formulations primarily relate to their release mechanisms, duration of action, and bioavailability: I) Immediate-release (IR) methylphenidate formulations, such as Ritalin^® IR, provide a rapid onset of action with a relatively short duration, typically lasting 3-4 hours. They are often administered multiple times a day (usually two to three times) to maintain therapeutic effects; these formulations are beneficial for patients who require flexible dosing or fine-tuning of dose throughout the day (ref. 3). II) Sustained-release (SR) and extended-release (ER) formulations, such as Ritalin SR^®, Concerta^®, Metadate CD^®, and Quillivant XR^®, are designed to extend the duration of action to 8-12 hours, reducing the need for multiple daily dosing. These formulations are favoured for their ability to maintain stable plasma concentrations throughout the day, which helps reduce the likelihood of peak-trough fluctuations that can lead to side effects or suboptimal symptom control. This also improves patient adherence by simplifying dosing regimens to once daily (ref. 4). Moreover, there are non-traditional formulations that provide ER methylphenidate in orally disintegrating tablet (ODT) or liquid forms and are particularly used useful in paediatric populations or individuals with difficulties swallowing tablets. III) Finally, there are available on the market transdermal patches that provide continuous release of methylphenidate over a 9-hour wear time: the onset of action is slower compared to oral formulations, but they offer the advantage of being removed if adverse effects occur, thereby controlling the duration of exposure (ref. 4).

Methylphenidate misusing issues

Consistently with an increasing prescription of methylphenidate, closely tied to rising ADHD diagnoses, its abuse and misuse are a growing concern (ref. 5, ref. 6), particularly among patients with dual diagnosis—those with concurrent psychiatric disorders and substance use disorders (SUD) (ref. 7–ref. 10). This is supported by findings recording the appearance of methylphenidate on the illicit market (ref. 11). Current literature available demonstrated varying prevalence rates of methylphenidate misuse among patients with dual diagnosis, often higher than in the general population (ref. 12). Reasons why it could be misused by students and young adults may include cognitive enhancement or recreational purposes (ref. 13–ref. 15). A systematic review by Kaye and Darke (2012) (ref. 16) reported that up to 25% of individuals with psychiatric disorders and concurrent SUD misused prescription stimulants, including methylphenidate. Another study by Levin et al. (2008) (ref. 17) found that approximately 30% of patients with ADHD and co-occurring SUD misused their prescribed stimulants. Research indicates that individuals with dual diagnosis are at an elevated risk for methylphenidate misuse, especially for those agents with pharmacologic and pharmacokinetic characteristics that provide a rapid high, primarily due to the overlapping features of ADHD and SUD, such as impulsivity and sensation-seeking behaviours (ref. 7, ref. 18, ref. 19).

Methylphenidate’s abuse liability is closely tied to its pharmacological action on the dopaminergic system, specifically its ability to inhibit the reuptake of dopamine (DA) and norepinephrine (NE) by binding to their respective transporters, particularly the dopamine transporter (DAT) and the norepinephrine transporter (NET) (ref. 20–ref. 22). This leads to an accumulation of dopamine in the synaptic cleft, which enhances dopaminergic neurotransmission. The dopaminergic pathways most affected by methylphenidate include the mesolimbic and mesocortical pathways, which are associated with reward, motivation, and executive function (ref. 21, ref. 22).

The main aim of the study was: understanding the prevalence and pattern of abuse/misuse of methylphenidate among patients with dual diagnosis (concurrent psychiatric disorder and SUD), and what are the associated clinical outcomes and risk factors.

Methodology

Systematic electronic searches were performed from August to September 2024 on PubMed and Scopus databases. The following search strategy was used: TITLE-ABS-KEY (methylphenidate OR Ritalin OR Concerta) AND TITLE-ABS-KEY (abuse OR misuse OR dependency OR addiction) AND TITLE-ABS-KEY (dual diagnosis OR comorbid psychiatric disorder OR psychiatric disorder AND substance use disorder). Moreover, other relevant papers not resulting from the described searches were added from references of included articles. The systematic review was structured in accordance with the PRISMA (ref. 23, ref. 24) guidelines and identified studies were assessed by title/abstract and full text screening against eligibility criteria (see PRISMA checklist in Supplementary Materials).

The eligibility criteria included the selection of exclusively original articles written in English that provide data on the abuse/misuse of methylphenidate among patients with dual diagnosis. The data were collected in an Excel table containing the first author’s name and year of publication of the study, study design, demographic variables (gender, age, psychiatric history) and eventual details on the abuse/misuse of the drug (e.g., dosage and route of administration). The exclusion criteria for both selection phases were: 1) non-original research (e.g., review, metanalysis, commentary, editorial, letter to the editor without data available, and book chapter); 2) non-full-text articles (e.g., meeting abstract); 3) language other than English; 4) animal/in vitro studies; 5) articles not relating to abuse/misuse of methylphenidate and dealing with a specific diagnosis of SUD co-occurring with a psychiatric disorder. The research was registered on PROSPERO with the following ID number: CRD42024576724.

In addition to the main aim of the study, other specific outcomes to be measured and analysed include data on prevalence of abuse/misuse of methylphenidate in the target population, e.g., frequency, rates, patterns of use, etc., but also clinical outcomes, such as the impact on psychiatric symptoms and overall mental health, the effects on SUD (e.g., exacerbation or mitigation of symptoms), the incidence of adverse events and complications (e.g., cardiovascular issues, psychological effects), and eventual risk factors (e.g., demographic factors, psychiatric and SUD profiles, social and environmental factors contributing to misuse). The research question was formulated following the PICO framework guidelines (Supplementary Materials Table 1). The population (P) includes patients affected with a dual diagnosis (co-occurring psychiatric disorder and SUD) misusing and abusing methylphenidate. The intervention (I) focuses on the rate of methylphenidate abuse/misuse in this specific population of patients, while the comparison (C) is made with the general population. The outcome (O) encompasses an understanding of the prevalence and pattern of abuse/misuse of methylphenidate among patients with dual diagnosis, and what are the associated clinical outcomes and risk factors. The research question was: “What are prevalence and patterns of methylphenidate abuse or misuse among patients with dual diagnosis, and what are the associated risk factors and clinical outcomes?”. The assessment of risk of bias was made in accordance with the Cochrane risk of bias 2 (RoB 2) tool. The analysis of the risk of bias among the twelve articles provided valuable insights into the complexities of methylphenidate abuse within populations with dual diagnoses (Supplementary Materials Table 2). Selection bias was generally mitigated in many studies through the inclusion of diverse patient demographics, such as different age groups, gender representations, and varying psychiatric histories. Although some studies utilised convenience sampling, they often focused on specific populations known to exhibit higher rates of substance use, thereby enhancing the relevance of their findings within these contexts. Measurement bias was addressed in several studies by incorporating structured interviews and standardised assessment tools, which increased the reliability of the reported data on methylphenidate misuse. While some articles relied on self-reported data, this approach was frequently supplemented with corroborating clinical assessments, minimising the potential for underreporting. The acknowledgment of potential measurement limitations by the authors also indicates a commitment to transparency and scientific rigor. Reporting bias was not prominently observed, as the majority of studies presented comprehensive findings and discussed both positive and negative outcomes associated with methylphenidate misuse. This balanced reporting fosters a more nuanced understanding of the issue, contributing to a broader dialogue in the field. Confounding bias was effectively managed in many studies by accounting for various psychiatric comorbidities and substance use histories. Some articles utilised statistical methods to control for confounders, thus enhancing the validity of their conclusions regarding the relationship between methylphenidate abuse and underlying psychiatric disorders.

In conclusion, the overall assessment suggests a low to moderate level of bias across the analysed articles.

Results

From a total of 1,330 articles (PubMed = 940; Scopus = 390; other sources = 0), after deduplication (n = 59), a total of 1,271 records were screened. Among the articles screened, 523 were considered not relevant to the subject after reading the title and abstract, 96 were not written in English and 322 were non-original articles. Of the 153 full-text articles assessed for eligibility, 140 did not match the inclusion criteria for our review; finally, 12 articles were included in the systematic review (f1).

Studies recorded were: one observational studies (N=1) (ref. 25), one case series (N=1) (ref. 26), three case reports (N=3) (ref. 27–ref. 29), three randomised controlled trials (N=3) (ref. 30–ref. 32), one survey (N=1) (ref. 33), one SPECT study (N=1) (ref. 34), one cross sectional study (N=1) (ref. 35), one longitudinal study (N=1) (ref. 36). A detailed summary of the 12 articles is included in T1.

Demographic findings showed a predominance of males (1,104/1,551). There were six studies reporting a mixed population (ref. 25, ref. 26, ref. 32, ref. 33, ref. 35, ref. 36), and none in women alone. The age of the subjects ranged from 13 to 65 years. Apart for the diagnosis of ADHD, most important psychiatric diagnoses were mainly relating to conduct disorders (N=5) (ref. 31–ref. 34, ref. 36), personality disorders (N=5) (ref. 25–ref. 27, ref. 30, ref. 35), major depression disorder (N=3) (ref. 29, ref. 32, ref. 34), anxiety disorders (N=3) (ref. 25, ref. 34, ref. 35), dysthymic disorder (N=1) (ref. 28), affective disorders (N=1) (ref. 35), autism spectrum disorder (N=1) (ref. 29), oppositional defiant disorder (N=1) (ref. 34), schizophrenic spectrum disorder (N=1) (ref. 35), anorexia nervosa (N=1) (ref. 29) and both psychotic and mood disorders (N=2) (ref. 25, ref. 29).

The prevalence of psychiatric/neurological symptoms is reported in T2.

A history of polysubstance use was reported in eight articles (N=8), including cannabis, cocaine, amphetamines, ketamine, heroin, nicotine (T3).

Eight of these articles were related to alcohol use disorder (N=8) (ref. 26–ref. 29, ref. 31, ref. 33, ref. 34, ref. 36). Five of these articles were related to Cocaine Use Disorder (N=5) (ref. 26, ref. 27, ref. 33–ref. 35). Four of these articles were related to Cannabis Use Disorder (N=4) (ref. 28, ref. 31, ref. 33, ref. 34). Three articles were related to nicotine dependence (N=3) (ref. 25, ref. 29, ref. 34). Heroin dependence was reported in one article (N=1) (ref. 33) as well as Stimulant Use Disorder (N=1) (ref. 30). Among the most commonly reported psychiatric/neurological symptoms, it is noteworthy that the appearance of anxious symptoms was reported in six articles (ref. 26, ref. 28–ref. 30, ref. 32, ref. 35). Signs and symptoms indicative of sympathetic nervous system stimulation were documented in four studies (ref. 26, ref. 28, ref. 30, ref. 35). Craving was noted in four other studies (ref. 25, ref. 30, ref. 32, ref. 35). Hallucinations were reported in three studies (ref. 26, ref. 27, ref. 30). Altered levels of consciousness were described in three studies (ref. 26, ref. 27, ref. 30), while agitation and violent behaviour were observed in two studies (ref. 26, ref. 30).

Concerning organic symptoms (T4), the most prevalent were gastrointestinal symptoms such as loss of appetite, weight loss, diarrhoea, epigastric pain, abdominal discomfort, and dry mouth (N=4) (ref. 29, ref. 30, ref. 32, ref. 35), followed by cardiovascular events, including palpitations, hypertension, chest pain, and dizziness (N=4) (ref. 26, ref. 30, ref. 32, ref. 35). Musculoskeletal symptoms, such as fatigue, muscle cramps, and psychomotor retardation, were reported in three studies (N=3) (ref. 29, ref. 30, ref. 35), while respiratory symptoms, including tachypnea, pulmonary hypertension, and pulmonary granulomatosis, were reported in two studies (N=2) (ref. 26, ref. 35).

No fatalities were reported; however, three hospitalizations due to suicidal intentions were documented (ref. 26, ref. 28, ref. 30). Of these, two were associated with oral abuse of methylphenidate (ref. 26, ref. 30), and one was linked to intranasal abuse of methylphenidate (ref. 28). Regarding the abuse of methylphenidate, the most common dosages ranged from 10 to 72 mg, with several cases reporting significantly higher amounts ranging from 100 to 400 mg (N=75/1,551) (N=4) (ref. 26, ref. 28, ref. 30, ref. 35), being normal dosages up to 60mg/day.

In terms of methylphenidate formulations, both ER (N=3) (ref. 32, ref. 34, ref. 36) and IR (N=1) (ref. 25) variants have been reported in cases of abuse. The most common was the ER formulation associated with “increased energy and feeling of satisfaction” (ref. 35). The primary routes of administration observed were oral ingestion (N=30), intravenous injection (N=11) and intranasal (N=9), with a notable preference for 60% of individuals opting for oral routes (ref. 26, ref. 34, ref. 35).

Discussion

According to the results of the study, the misuse of methylphenidate in this population often involves its non-medical use (ref. 25, ref. 26, ref. 28, ref. 29, ref. 35, ref. 36), non-conventional routes of administration (ref. 26, ref. 28, ref. 35) e.g., intranasal or intravenous, and polysubstance abuse to potentiate or modulate the effects of methylphenidate. Eight of the twelve articles reported cases of polysubstance use (ref. 25, ref. 26 ,ref. 28, ref. 29, ref. 34–ref. 36), with methylphenidate often co-abused with alcohol, cocaine, cannabis, and nicotine. The most important SUD associated with misuse of methylphenidate is alcohol use disorder, reported in eight of the twelve studies (ref. 26–ref. 29, ref. 31, ref. 33, ref. 34, ref. 36), followed by cocaine use disorder, reported in five studies (ref. 26, ref. 27, ref. 33–ref. 35), and cannabis use disorder, found in four studies (ref. 28, ref. 31, ref. 33, ref. 34). These findings suggest that methylphenidate misuse, particularly among individuals with dual diagnosis, is often associated with other substance dependencies. Moreover, recent research highlights an exponential increase in the prevalence of ADHD diagnoses, which in turn suggests that the number of individuals treated with methylphenidate will rise accordingly. The general public has become more aware of ADHD leading people to bring up their concerns to a physician, which in turn might prompt more numbers of people to be diagnosed and to prescribe the treatment (ref. 37). Additionally, Google Trends data indicate a marked increase in ADHD diagnoses since 2004, reflecting a growing recognition and awareness of the disorder (ref. 38). As a result, the potential for misuse of methylphenidate is expected to grow, posing a heightened risk within vulnerable populations such as those with dual diagnosis. This further emphasises the need for more robust prevention strategies, including better monitoring of prescriptions and improved patient education to mitigate these risks.

The misuse of methylphenidate among individuals with dual diagnosis appeared associated with several adverse clinical outcomes. Sympathetic nervous system stimulation, reported in four of the reviewed studies (ref. 26, ref. 28, ref. 30, ref. 35), was frequently associated with cardiovascular complications, including hypertension, tachycardia, and cognitive impairment. Methylphenidate misuse has also been linked to the exacerbation of psychiatric symptoms such as anxiety, depression, and mood disorders, as well as an increased risk of addiction due to its reinforcing effects. Consistently, findings from Shellenberg et al. (2020) (ref. 39) indicate that methylphenidate misuse is associated with worsening anxiety and depressive symptoms in patients with co-occurring psychiatric disorders, thereby amplifying mood instability. Additionally, the reinforcing effects of methylphenidate linked to an increase in dopamine release, particularly in individuals with ADHD (ref. 40), elevates its addictive potential, especially in individuals predisposed to SUD. Similarly, reinforcing effects have been associated to other medications, if administered at high dosage or unconventional routes, e.g. bupropion, a norepinephrine-dopamine reuptake inhibitor antidepressant, has also shown reinforcing properties due to its ability to increase dopamine levels, which can lead to misuse and dependence (ref. 41).

Several factors contributing to the increased risk of methylphenidate misuse among individuals with dual diagnoses have been identified (f2). These include the severity of ADHD and psychiatric symptoms, a history of substance abuse, and various social and environmental influences such as peer pressure, easy access to medications, and stressful life events. Additional risk factors include early-onset substance abuse (ages 13-18), polysubstance abuse, late ADHD diagnosis, and sometimes preexisting mental health conditions and psychiatric comorbidities, particularly personality traits characterised by impulsivity and sensation-seeking, which are common in both ADHD and SUD, which may further increase the risk of future misuse. The analysis of risk factors associated with methylphenidate misuse revealed several key contributors. Indeed, social and family factors, such as a family history of psychiatric disorders, emerged as the most prevalent risk factor, with 1,355 patients in a population sample of 1,551 patients (ref. 25, ref. 27–ref. 32, ref. 34, ref. 36). This was followed by psychiatric comorbidity, recorded in 1,061 patients, which includes diagnoses such as personality disorders, anxiety, and major depression, often exacerbating the likelihood of misuse. Interestingly, in the adolescent sample of patients, the most recorded diagnosis was a conduct disorder (ref. 31–ref. 34, ref. 36), while among adults most common diagnoses were anxiety/mood disorders (ref. 25, ref. 29), personality disorders (ref. 25–ref. 27, ref. 30, ref. 35) and schizophrenic spectrum disorder (ref. 35). Moreover, early substance use (13-18 years) was reported in 952/1,551 patients, highlighting how exposure to substances at a young age can significantly influence later patterns of substance abuse (ref. 25, ref. 26, ref. 30, ref. 31, ref. 33 ,ref. 36). Consistently, adolescent misuse of prescription stimulants is indeed associated with increased risk of later prescription drug (e.g. opioids and sedatives) misuse, This link is influenced by several factors, including the adolescent’s social environment, psychological stressors, and even genetic predispositions (ref. 42). Polysubstance abuse and unhealthy lifestyle choices (e.g., malnutrition and alcohol use) were still notable, affecting 477 and 379 patients, respectively. The unique environment of prisons, characterised by stress, limited access to healthcare, and a higher prevalence of substance use disorders, can exacerbate the potential for misuse. These patients may have a history of substance abuse and impulsive behaviour, increasing their vulnerability to misusing prescribed medications (ref. 30). This underscores the importance of monitoring and support for individuals with dual diagnosis in these settings to mitigate the risks associated with methylphenidate misuse.

Non-conventional routes of administration, e.g. intranasal, or intravenous, were recorded; these significantly influences the onset, intensity, and duration of effects, and overall the misuse pattern of methylphenidate. Indeed, if stimulants like methylphenidate are snorted or injected, patients may experience a rapid onset of euphoria, which can enhance their potential for misuse (ref. 43). According to the findings of the systematic review, both ER and IR formulations of methylphenidate were reported in cases of misuse; however it appears that ER formulations may be less prone to abuse due to their slower onset and longer duration of action. ER formulations were here associated with more controlled experiences of “increased energy” or “feelings of satisfaction,” whereas IR formulations were more often linked to rapid onset and intense effects, potentially increasing their misuse potential. IR formulations were often crushed and inhaled or injected for non-medical use, leading to a quicker and more potent euphoric effect. The slower onset and prolonged effects of the ER formulations made them less desirable for abuse (ref. 12, ref. 44). Similar to the use of IR methylphenidate, IR quetiapine is associated with a higher risk of misuse due to the quick onset of effects that can lead to feelings of sedation and euphoria, making it more susceptible to abuse compared to its ER formulation (ref. 45). Both medications exhibit increased misuse potential due to their rapid effects, while their ER counterparts provide more stable and controlled therapeutic outcomes, reducing the likelihood of misuse.

Harm Reduction Strategies and Prevention of abuse/misuse of methylphenidate

Regulatory strategies play a critical role in preventing the misuse of medications. Integrating behavioural therapies alongside pharmacological treatment can enhance the effectiveness of prevention strategies. Cognitive-behavioural therapy (CBT) has been shown to reduce substance use providing patients with tools to resist the urge to misuse their medications. Open communication regarding potential side effects and misuse can empower patients to take an active role in their treatment reducing the likelihood of substance abuse. Multifaceted approach that includes education, screening, behavioural therapy, and collaborative care can significantly mitigate the risk of stimulant misuse and improve overall patient outcomes (ref. 46).

As highlighted by the Italian Medicines Agency (ref. 47), a global regulatory approach is essential to mitigate the phenomenon of drug abuse, particularly through coordinated efforts across different healthcare sectors. One of the key strategies reported was the implementation of Prescription Monitoring Programs (PMPs), which enable regulators and healthcare providers to monitor the prescribing of controlled substances, including stimulants, and assist in identifying patterns of overprescription. Such monitoring can prevent patients from obtaining multiple prescriptions, a known risk factor for abuse. Additionally, the implementation of Risk Evaluation and Mitigation Strategies (REMS) was reported, which are designed to ensure that the benefits of specific medications outweigh their associated risks. Education and awareness campaigns were also highlighted, aimed at increasing awareness of the risks related to the misuse of stimulant medications (ref. 48). The FDA recommends that healthcare providers counsel patients against sharing medications and monitor for signs of diversion. They have mandated updates to warning labels across stimulant medications to enhance awareness of misuse risks and to promote safe storage and disposal practices (ref. 49). The EUDA (European Union Drugs Agency) provides various guidelines and strategies aimed at harm reduction and prevention of drug misuse, particularly focusing on the diverse interventions necessary to tackle drug-related issues across Europe. One of the key frameworks established by the EUDA is the classification of prevention interventions into three main categories: universal, selective, and indicated. Universal prevention targets the entire population to deter or delay substance use onset, while selective prevention focuses on vulnerable groups at higher risk. Indicated prevention aims at individuals to prevent the development of substance dependence and reduce harmful use (ref. 50). Implementing these strategies can help mitigate the risks associated with stimulant medications, including methylphenidate.

Strengths and limitations of the study

This systematic review is pioneering in its investigation of the abuse and misuse of methylphenidate specifically within the context of dual diagnosis patients. By synthesising data from twelve original studies, this review highlights the significance of understanding the prevalence and characteristics of methylphenidate abuse, contributing valuable insights that are crucial for the prevention of SUD in this vulnerable population. The novelty of the findings underscores the urgent need for healthcare providers to recognize the potential risks associated with methylphenidate, particularly its misuse at high doses or through non-oral routes. Given the substantial health risks associated with methylphenidate abuse, including addiction and adverse health outcomes, the data presented in this study provide an essential foundation for developing strategies aimed at improving patient monitoring, regulatory measures, prevention and psychoeducation. However, certain limitations must be acknowledged. There is a potential for publication bias, as the review exclusively included studies published in English, which may have resulted in the exclusion of relevant research available in other languages. Moreover, the phenomenon of methylphenidate abuse may be underestimated, particularly in cases with unclear or incomplete medical histories, where detection challenges could lead to under-recognition of the issue. These factors may limit the generalizability of the findings. Nonetheless, the insights derived from this review pave the way for future research and clinical practices, highlighting the need for careful monitoring and regulation of methylphenidate prescriptions in dual diagnosis patients to mitigate risks effectively.

Conclusion

While it is an effective treatment for ADHD and other conditions, methylphenidate potential for abuse, particularly at high doses or via non-oral routes, in dual diagnosis patients underscores the importance of careful monitoring and regulation. The misuse of methylphenidate is associated with substantial risks, including addiction, adverse health outcomes, and broader public health concerns. While it is an effective treatment for ADHD, methylphenidate’s potential for abuse, particularly at high doses or via non-oral routes, in dual diagnosis patients underscores the importance of careful monitoring and regulation. The misuse of methylphenidate is associated with substantial risks, including addiction, adverse health outcomes, and broader public health concerns. To mitigate these risks, it is crucial to prioritise the use of extended-release (ER) formulations in dual diagnosis patients, as they offer a lower potential for abuse. Additionally, increasing the frequency of patient monitoring visits can help identify and address early signs of misuse. Effective psychoeducation at the beginning of treatment is also essential to ensure patients are well-informed about the risks and safe use of the medication. This should also include clear communication regarding the importance of adhering to prescribed doses increasing the awareness about the potential dangers of misuse. Addressing these risks requires a comprehensive approach, including stricter prescription monitoring, patient education about the risks of misuse, and more effective regulatory controls to prevent diversion in this vulnerable population.

References

1. Summary of product characteristics(. 2009
2. Prescribing information(. 2013
3. RCF Cândido, CA Menezes de Padua, S Golder, DR Junqueira. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.. Cochrane Database systematic Rev. (, 2021. [DOI]
4. M Moharram, T Kiang. Pharmacokinetics of long-acting methylphenidate: formulation differences, bioequivalence, interchangeability.. Eur J Drug Metab Pharmacokinet. (, 2024. [DOI]
5. AYL Chan, TT Ma, WCY Lau, P Ip, D Coghill, L Gao. Attention-deficit/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study.. EClinicalMedicine. (, 2023. [DOI | PubMed]
6. DEA releases 2024 national drug threat assessment(. 2024
7. M Barbuti, M Maiello, V Spera, A Pallucchini, GE Brancati, AGI Maremmani. Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician.. J Clin Med. (, 2023. [DOI | PubMed]
8. GM Bright. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey.. Medscape J Med. (, 2008. [PubMed]
9. DB Clemow. Misuse of methylphenidate. In:. Non-Medical and Illicit Use of Psychoactive Drugs, vol., 2015. [DOI]
10. E Frauger, D Amaslidou, M Spadari, V Allaria-Lapierre, D Braunstein, V Sciortino. Patterns of methylphenidate use and assessment of its abuse among the general population and individuals with drug dependence.. Eur Addict Res. (, 2016. [DOI]
11. J Carlier, R Giorgetti, MR Varì, F Pirani, G Ricci, FP Busardò. Use of cognitive enhancers: methylphenidate and analogs.. Eur Rev Med Pharmacol Sci. (, 2019. [DOI]
12. TE Wilens, LA Adler, J Adams, S Sgambati, J Rotrosen, R Sawtelle. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.. J Am Acad Child Adolesc Psychiatry. (, 2008. [DOI | PubMed]
13. SE McCabe, JR Knight, CJ Teter, H Wechsler. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey.. Addict (Abingdon England). (, 2005. [DOI]
14. LM Garnier-Dykstra, KM Caldeira, KB Vincent, KE O’Grady, AM Arria. Nonmedical use of prescription stimulants during college: four-year trends in exposure opportunity, use, motives, and sources.. J Am Coll health: J ACH. (, 2012. [DOI]
15. CJ Teter, SE McCabe, JA Cranford, CJ Boyd, SK Guthrie. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample.. J Am Coll health: J ACH. (, 2005. [DOI]
16. S Kaye, S Darke. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?. Addict (Abingdon England). (, 2012. [DOI]
17. FR Levin, SM Evans, DJ Brooks, AS Kalbag, F Garawi, EV Nunes. Treatment of methamphetamine dependence with bupropion: A pilot study.. J Clin Psychopharmacol. (, 2008
18. A Bahji. Navigating the complex intersection of substance use and psychiatric disorders: A comprehensive review.. J Clin Med. (, 2024. [DOI | PubMed]
19. L Tschudi, SKM Fischer, E Perlov, MR Baumgartner, M Soyka, TJ Müller. Concomitant Drug Use among Opioid-Dependent Patients with and without Attention Deficit Hyperactivity Disorder: Does Methylphenidate Merit a Trial?. Eur Addict Res. (, 2023. [DOI]
20. AH Ashok, Y Mizuno, ND Volkow, OD Howes. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis.. JAMA Psychiatry. (, 2017. [DOI]
21. ND Volkow, JS Fowler, GJ Wang, YS Ding, SJ Gatley. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.. Eur Neuropsychopharmacol. (, 2002. [DOI]
22. TSC Zetterström, E Quansah, M Grootveld. Effects of methylphenidate on the dopamine transporter and beyond.. Curr topics Behav Neurosci. (, 2022. [DOI]
23. L Shamseer, D Moher, M Clarke, D Ghersi, A Liberati, M Petticrew. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.. BMJ (Clinical Res ed.). (, 2015. [DOI]
24. MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.. BMJ (Clinical Res ed.). (, 2021. [DOI]
25. TI Bron, D Bijlenga, MV Kasander, AT Spuijbroek, AT Beekman, JJ Kooij. Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study.. Eur Neuropsychopharmacol. (, 2013. [DOI]
26. M Bruggisser, M Bodmer, ME Liechti. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets.. Swiss Med weekly. (, 2011. [DOI]
27. L Grau-López, C Roncero, MC Navarro, M Casas. Psychosis induced by the interaction between disulfiram and methylphenidate may be dose dependent.. Subst Abuse. (, 2012. [DOI]
28. SL Jaffe. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD.. J Am Acad Child Adolesc Psychiatry. (, 1991. [DOI]
29. L Lalanne, L Weiner, B Trojak, F Berna, G Bertschy. Substance-use disorder in high-functioning autism: clinical and neurocognitive insights from two case reports.. BMC Psychiatry. (, 2015. [DOI | PubMed]
30. M Konstenius, N Jayaram-Lindström, J Guterstam, O Beck, B Philips, J Franck. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.. Addict (Abingdon England). (, 2014. [DOI]
31. L Tamm, K Trello-Rishel, P Riggs, PA Nakonezny, M Acosta, G Bailey. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.. J Subst Abuse Treat. (, 2013. [DOI]
32. TM Winhusen, DF Lewis, PD Riggs, RD Davies, LA Adler, S Sonne. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.. J Child Adolesc Psychopharmacol. (, 2011. [DOI]
33. SM Gordon, F Tulak, J Troncale. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence.. J Addictive Dis. (, 2004. [DOI]
34. CM Szobot, MC Shih, T Schaefer, N Júnior, MQ Hoexter, YK Fu. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder–a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.. NeuroImage. (, 2008. [DOI]
35. M Vogel, P Bucher, J Strasser, ME Liechti, S Krähenbühl, KM Dürsteler. Similar and different? Subjective effects of methylphenidate and cocaine in opioid-maintained patients.. J psychoactive Drugs. (, 2016. [DOI | PubMed]
36. TE Wilens, M Gignac, A Swezey, MC Monuteaux, J Biederman. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications.. J Am Acad Child Adolesc Psychiatry. (, 2006. [DOI]
37. E Abdelnour, MO Jansen, JA Gold. ADHD diagnostic trends: increased recognition or overdiagnosis?. Missouri Med. (, 2022
38. ADHD diagnosis(. 2024
39. TP Shellenberg, WW Stoops, JA Lile, CR Rush. An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.. Expert Rev Clin Pharmacol. (, 2020. [DOI]
40. ND Volkow, JM Swanson. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.. Am J Psychiatry. (, 2003. [DOI]
41. S Chiappini, F Schifano. What about “Pharming”? Issues regarding the misuse of prescription and over-the-counter drugs.. Brain Sci. (, 2020. [DOI | PubMed]
42. SE McCabe, JE Schulenberg, TE Wilens, TS Schepis, KS Werner, VV McCabe. Attention-deficit hyperactivity disorder stimulant therapy and prescription drug misuse during transition to young adulthood.. Psychiatr Serv (Washington D.C.). (, 2024. [DOI]
43. J Burtner, M Behling, T Cassidy, SF Butler. Prevalence of nonmedical use and routes of administration for prescription stimulant medications among adults in a substance abuse treatment population.. J Addictive Dis. (, 2018. [DOI]
44. DA Parasrampuria, KA Schoedel, R Schuller, J Gu, P Ciccone, SA Silber. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.. J Clin Pharmacol. (, 2007. [DOI]
45. F Schifano, S Chiappini, JM Corkery, A Guirguis. Abuse of prescription drugs in the context of novel psychoactive substances (NPS): A systematic review.. Brain Sci. (, 2018. [DOI | PubMed]
46. M Nation, C Crusto, A Wandersman, KL Kumpfer, D Seybolt, E Morrissey-Kane. What works in prevention. Principles of effective prevention programs.. Am Psychol. (, 2003. [DOI]
47. Abuso di farmaci oppioidi: una strategia regolatoria globale per mitigare il fenomeno(. 2016
48. RM Califf, J Woodcock, S Ostroff. A proactive response to prescription opioid abuse.. New Engl J Med. (, 2016. [DOI]
49. Califf, FDA top officials call for sweeping review of agency opioids policies(. 2016
50. The European drug report 2024: Trends and developments(. 2011